Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report - Takeaways - MDSpire

Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report

  • By

  • Tianling Shang

  • Bo Ma

  • Shumei Wen

  • Zuohong Tang

  • Xiaoliang Mao

  • Keping Jiao

  • June 29, 2026

  • 0 min

Share

  • 1

    Anti-IgLON5 disease is characterized by autoantibodies targeting the IgLON5 protein and presents with diverse neurological symptoms.

  • 2

    The case report details a 53-year-old male with generalized myokymia as a rare manifestation of anti-IgLON5 disease.

  • 3

    The patient tested positive for anti-IgLON5 IgG antibodies in serum and cerebrospinal fluid, with no significant MRI abnormalities.

  • 4

    Treatment with an FcRn antagonist and oral glucocorticoids led to rapid alleviation of myokymia and a decline in antibody titers.

  • 5

    This case highlights the importance of screening for neuronal autoantibodies in myokymia and suggests a potential new treatment approach.

Original Source(s)

Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report

  • by Tianling Shang, Bo Ma, Shumei Wen, Zuohong Tang, Xiaoliang Mao, Keping Jiao

  • June 29, 2026

Related Content

From brain scans to classifiers: A systematic review of ML-based autism diagnostic frameworks

Immune niche-associated and niche-regulated plasticity in glioblastoma: state transitions, immune escape, and therapeutic vulnerabilities

Cardiovascular risk factors and carotid plaque components in a multi-ethnic cohort using 3 Tesla MRI: the HELIUS study